Desentum’s Phase I trial saw nearly all patients in the trial reaching their targeted maximum dose of pollen allergy vaccine, DM-101PX.

Patient engagement through advisory boards, surveys, and listening sessions can help address industry challenges like trial delays.

Alkermes has begun a randomised Phase II trial to assess the efficacy and safety of ALKS 2680 in adults with idiopathic ...

Initial results from the ongoing trial saw one patient achieving a complete response in the trial combining Tovecimig with ...

Moleculin Biotech has begun dosing subjects in a Phase III trial of Annamycin with Cytarabine for treating acute myeloid ...

The pivotal, Phase III study will evaluate the change in average daily “OFF” time in Parkinson's patients dosed with ...

Yingli Pharma has obtained US FDA approval for a Phase III trial of linperlisib for R/R peripheral T-cell lymphoma (PTCL).

AstraZeneca’s AZD0780 is an investigational oral medication that was developed to lower low-density lipoprotein cholesterol ...

A recent study has shown that one dose of Bavarian Nordic’s Jynneos vaccine was overall 58% effective at preventing mpox ...

Three patients living with hypertrophic cardiomyopathy have had their disease classification downgraded following a single ...

Vaxcyte is awaiting data from another vaccine candidate for invasive pneumococcal disease (IPD) before advancing to Phase III ...

Corcept's Phase III trial of relacorilant with nab-paclitaxel has met its primary endpoint, demonstrating an improvement in ...